Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Elexacaftor/tezacaftor/ivacaftor’s effects on cystic fibrosis infections are maintained, but not increased, after 3.5 years of treatment
Sarah J. Morgan, … , Pradeep K. Singh, the PROMISE-Micro Study Group
Sarah J. Morgan, … , Pradeep K. Singh, the PROMISE-Micro Study Group
Published September 5, 2024
Citation Information: J Clin Invest. 2024;134(20):e184171. https://doi.org/10.1172/JCI184171.
View: Text | PDF
Research Letter Microbiology

Elexacaftor/tezacaftor/ivacaftor’s effects on cystic fibrosis infections are maintained, but not increased, after 3.5 years of treatment

  • Text
  • PDF
Abstract

Authors

Sarah J. Morgan, Ellis Coulter, Hannah L. Betts, George M. Solomon, John P. Clancy, Steven M. Rowe, David P. Nichols, Pradeep K. Singh, the PROMISE-Micro Study Group

×

Figure 1

Sputum microbiology after ETI.

Options: View larger image (or click on image) Download as PowerPoint
Sputum microbiology after ETI.
(A) Proportion of participants culture po...
(A) Proportion of participants culture positive for indicated pathogens (includes participants missing data at visit). *P < 0.05 by McNemar’s exact test. (B) Proportion of baseline-positive participants becoming repeatedly negative for indicated pathogen by culture (C) or culture and ddPCR (C&dd); n = number of participants analyzed. (C–H) Culture density in participants who were baseline culture positive for indicated pathogens including (C, E, and G) and not including (D, F, and H) culture-negative samples. Similar differences were apparent between all-data vs. data with culture-negative samples eliminated in by-participant averages (Supplemental Figure 1, C–H). Individual participants are indicated in black, averages in red. The limit of detection = 20 CFU/g. *P < 0.05 vs. baseline; #P < 0.05 vs. 1 month by mixed-effects analysis (C–H).

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts